Cell line name |
HCT 116_6244R |
Synonyms |
H6244-R; H6244-R1; HCT116R_6244R |
Accession |
CVCL_C3GI |
Resource Identification Initiative |
To cite this cell line use: HCT 116_6244R (RRID:CVCL_C3GI) |
Comments |
Population: Caucasian. Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244). Omics: Transcriptome analysis by RNAseq. Derived from site: In situ; Colon; UBERON=UBERON_0001155. |
Sequence variations |
- Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 9277; PPM1D; Simple; p.Leu450Ter (c.1349delT) (p.Leu450fs) (c.1344delT); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line).
|
Disease |
Colon carcinoma (NCIt: C4910) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_0291 (HCT 116) |
Sex of cell |
Male |
Age at sampling |
48Y |
Category |
Cancer cell line |
Publications | PubMed=21447798; DOI=10.1126/scisignal.2001752 Little A.S., Balmanno K., Sale M.J., Newman S., Dry J.R., Hampson M., Edwards P.A.W., Smith P.D., Cook S.J. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci. Signal. 4:Ra17.1-Ra17.15(2011) PubMed=31048689; DOI=10.1038/s41467-019-09438-w Sale M.J., Balmanno K., Saxena J., Ozono E., Wojdyla K., McIntyre R.E., Gilley R., Woroniuk A., Howarth K.D., Hughes G., Dry J.R., Arends M.J., Caro P., Oxley D., Ashton S., Adams D.J., Saez-Rodriguez J., Smith P.D., Cook S.J. MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF(V600E) amplification whereas KRAS(G13D) amplification promotes EMT-chemoresistance. Nat. Commun. 10:2030.1-2030.22(2019) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_C3GI
|
Encyclopedic resources |
Wikidata; Q114311571
|
Gene expression databases |
GEO; GSM3591762
|
Entry history |
Entry creation | 22-Sep-2022 |
Last entry update | 05-Oct-2023 |
Version number | 5 |
---|